Axonics’ (AXNX) Hold Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of Axonics (NASDAQ:AXNX) in a report published on Friday morning,Benzinga reports.

Axonics Trading Down 0.0 %

NASDAQ:AXNX opened at $70.42 on Friday. The stock has a market capitalization of $3.60 billion, a PE ratio of -586.83 and a beta of 0.82. The firm has a fifty day simple moving average of $69.70 and a 200 day simple moving average of $68.46. Axonics has a 1-year low of $49.70 and a 1-year high of $70.75.

Insider Buying and Selling

In other Axonics news, CFO Kari Leigh Keese sold 2,961 shares of the stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $69.41, for a total transaction of $205,523.01. Following the transaction, the chief financial officer now owns 40,362 shares in the company, valued at $2,801,526.42. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.85% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Axonics

A number of large investors have recently added to or reduced their stakes in AXNX. Edgestream Partners L.P. bought a new position in Axonics in the 1st quarter valued at about $605,000. Janus Henderson Group PLC increased its holdings in Axonics by 637.7% in the 1st quarter. Janus Henderson Group PLC now owns 178,322 shares of the company’s stock worth $12,298,000 after purchasing an additional 154,149 shares in the last quarter. Gabelli Funds LLC acquired a new position in shares of Axonics during the first quarter worth $12,271,000. Cowen AND Company LLC acquired a new stake in Axonics during the 2nd quarter valued at approximately $605,000. Finally, Bank of New York Mellon Corp boosted its position in shares of Axonics by 12.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 218,171 shares of the company’s stock valued at $14,668,000 after purchasing an additional 23,460 shares in the last quarter. Institutional investors and hedge funds own 99.48% of the company’s stock.

Axonics Company Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.